The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model R Abdelnabi, CS Foo, SJF Kaptein, X Zhang, TND Do, L Langendries, ... EBioMedicine 72, 2021 | 122 | 2021 |
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents TND Do, K Donckers, L Vangeel, AK Chatterjee, PA Gallay, MD Bobardt, ... Antiviral research 192, 105122, 2021 | 51 | 2021 |
Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients M Khan, M Clijsters, S Choi, W Backaert, M Claerhout, F Couvreur, ... Neuron 110 (23), 3919-3935. e6, 2022 | 38 | 2022 |
Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost … CP Nguyen, TND Do, R Bruggemann, J Ten Oever, E Kolwijck, ... International journal of antimicrobial agents 54 (6), 790-797, 2019 | 38 | 2019 |
Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues L Persoons, E Vanderlinden, L Vangeel, X Wang, NDT Do, SYC Foo, ... Antiviral research 193, 105127, 2021 | 30 | 2021 |
Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial L Liesenborghs, I Spriet, D Jochmans, A Belmans, I Gyselinck, ... EBioMedicine 66, 2021 | 26 | 2021 |
SARS-CoV-2 virion infectivity and cytokine production in primary human airway epithelial cells TND Do, S Claes, D Schols, J Neyts, D Jochmans Viruses 14 (5), 951, 2022 | 7 | 2022 |
Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411 R Konkel, A Milewska, NDT Do, EB Duran, A Szczepanski, J Plewka, ... Antiviral Research 219, 105731, 2023 | 2 | 2023 |
Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens” L Liesenborghs, I Spriet, D Jochmans, A Belmans, I Gyselinck, ... EBioMedicine 69, 2021 | 1 | 2021 |
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell … TND Do, R Abdelnabi, B Boda, S Constant, J Neyts, D Jochmans bioRxiv, 2024 | | 2024 |
itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens (vol 66, 103288, 2021) L Liesenborghs, I Spriet, D Jochmans, A Belmans, I Gyselinck, ... Ebiomedicine 69, 2021 | | 2021 |